Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 8:12:1030366.
doi: 10.3389/fonc.2022.1030366. eCollection 2022.

Latest updates on cellular and molecular biomarkers of gliomas

Maroun Bou Zerdan  1 , Ali Atoui  2 , Ali Hijazi  2 , Lynn Basbous  2 , Reine Abou Zeidane  2 , Saada M Alame  3 , Hazem I Assi  2
Affiliations
Review

Latest updates on cellular and molecular biomarkers of gliomas

Maroun Bou Zerdan et al. Front Oncol. .

Abstract

Gliomas are the most common central nervous system malignancies, compromising almost 80% of all brain tumors and is associated with significant mortality. The classification of gliomas has shifted from basic histological perspective to one that is based on molecular biomarkers. Treatment of this type of tumors consists currently of surgery, chemotherapy and radiation therapy. During the past years, there was a limited development of effective glioma diagnostics and therapeutics due to multiple factors including the presence of blood-brain barrier and the heterogeneity of this type of tumors. Currently, it is necessary to highlight the advantage of molecular diagnosis of gliomas to develop patient targeted therapies based on multiple oncogenic pathway. In this review, we will evaluate the development of cellular and molecular biomarkers for the diagnosis of gliomas and the impact of these diagnostic tools for better tailored and targeted therapies.

Keywords: biomarkers; circulating tumor DNA; circulating tumor cells; gliomas; immune microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Nuclear and transmembrane biomarkers as prognostic factors in gliomas. Biomarkers in red are poor prognostic factors. Biomarkers in green are good prognostic factors.*used to distinguish between oligodendroglioma and astrocytoma.
See this image and copyright information in PMC

References

    1. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol (2019) 15(7):405–17. doi: 10.1038/s41582-019-0220-2 - DOI - PMC - PubMed
    1. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. . Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin (2021) 71(5):381–406. doi: 10.3322/caac.21693 - DOI - PubMed
    1. Perez A, Huse JT. The evolving classification of diffuse gliomas: World health organization updates for 2021. Curr Neurol Neurosci Rep (2021) 21(12):67. doi: 10.1007/s11910-021-01153-8 - DOI - PubMed
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. . The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol (2021) 23(8):1231–51. doi: 10.1093/neuonc/noab106 - DOI - PMC - PubMed
    1. Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. . Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer (2022) 21(1):39. doi: 10.1186/s12943-022-01513-z - DOI - PMC - PubMed